HTG Molecular Diagnostics has obtained ISO 13485:2003 certification for the design, manufacture, and distribution of its patented qNPA technology-based products and services used in the analysis of gene expression. qNPA molecular ...
Tags: ISO Certification, analysis of gene expression, medical technology
HTG Molecular Diagnostics has partnered John Wayne Cancer Institute (JWCI) to sell its HTG melanoma signature assays. The signature assays are intended to be useful for diagnostic and prognostic applications along the melanoma continuum. ...
Tags: HTG Molecular, JWCI, melanoma signature, signature assays
HTG Molecular Diagnostics has collaborated with John Wayne Cancer Institute (JWCI) to market its HTG melanoma signature assays. The signature assays may be useful for diagnostic and prognostic applications along the melanoma ...
Tags: HTG melanoma signature assays, clinical technology, clinical research
HTG Molecular Diagnostics has gained rights to commercialize the Centre of Excellence for the Prevention of Organ Failure's(PROOF Centre)-developed gene expression blood tests,following the finalization of the license agreement. The gene ...
Tags: HTG Molecular Diagnostics, Prevention of Organ Failure, COPD, qNPA
HTG Molecular Diagnostics is set to launch the fully-automated EDGE system at the AMP conference, which will be held in Long Beach, California, US, from 25-27 October 2012. The instrument, which is designed for use in clinical and ...
Tags: fully-automated EDGE system, EDGE instrument, AMP conference
HTG Molecular Diagnostics has licensed Merck's breast cancer marker to develop, manufacture, and market breast cancer diagnostic tests. HTG Molecular Diagnostics CEO TJ Johnson said the ability to quickly, and locally assess a patient's ...